A.M. Edition for May 7. WSJ’s Caitlin Ostroff on investors’ hunt for the next crypto winner. WSJ’s Rochelle Toplensky discusses healthcare stocks after global calls to waive Covid-19 vaccine patents. And, ham-radio enthusiasts are seeking far-off destinations. Marc Stewart hosts.
Five stories to know for May 6: Biden reverses COVID vaccine patents, federal judge puts hold on ruling voiding U.S. moratorium on evicting renters, Liz Cheney warns the Republican Party, China on G7, and COVID spreads in rural India.
1. President Joe Biden threw his support behind waiving intellectual property rights for COVID-19 vaccines, bowing to mounting pressure from Democratic lawmakers and more than 100 other countries, but angering pharmaceutical companies.
2. A federal judge threw out the U.S. Centers for Disease Control and Prevention’s nationwide moratorium on evictions but agreed to put a temporary hold on her ruling as the government seeks to reverse the decision on appeal.
3. Representative Liz Cheney warned that her Republican Party is “at a turning point” as it prepares to try to remove her from leadership for rejecting former President Donald Trump’s false claims the election was stolen from him.
4. China condemned a joint statement by G7 foreign ministers that expressed support for Chinese-claimed Taiwan and cast Beijing as a bully, saying it was a gross interference in China’s internal affairs.
5. Hopes that India’s deadly second wave of COVID-19 was about to peak were swept away as it posted record daily infections and deaths and as the virus spread from cities to villages.
India has put vaccine distribution to other countries on hold as the country battles the world’s fastest-growing Covid-19 surge. The delay in distribution is hampering the global vaccination effort. Photo illustration: Laura Kammermann
Vaccines are medicines that train the body to defend itself against future disease, and they have been saving human lives for hundreds of years. Vaccines are medicines that train the body to defend itself against future disease.
A growing number of colleges around the country will require students to get Covid-19 vaccinations before returning to campus. But the policies are igniting a debate over whether businesses and institutions like schools can make vaccines a condition of attendance. Photo: Northeastern University
Chinese Covid-19 vaccines offer relatively low levels of protection compared with some of their foreign rivals. Here is why China is joining other countries in considering mixing and matching vaccines as a key to overcoming multiple vaccination challenges at once. Illustration: Ksenia Shaikhutdinova
Exclusive: Inside the facilities making the world’s most prevalent COVID-19 vaccine https://ti.me/3grX0v9
The risk of dying from COVID is much higher than getting a blood clot from a vaccine. But even more concerning is a new report from Oxford University that shows catching the coronavirus puts you at even more risk of a deadly blood clot. Each delay puts more lives at risk, as the coronavirus spreads. It’s a balancing act between speed and caution in the fight against COVID-19.
The rollout of the Johnson & Johnson vaccine has been paused in the US, Europe and South Africa after reports of rare blood clotting in a very small number of people. Health authorities said they were halting the use of the shot while they investigate the cases — and that they were doing this out of “an abundance of caution.” The Astra Zeneca jab was also recently temporarily suspended in some countries after being linked to rare blood clots. Authorities are calling it a short “pause.” The US’s Johnson and Johnson vaccine has hit the same stumbling block as the UK’s AstraZeneca jab did last month: a likely link to a rare and deadly blood clot. Use of Johnson and Johnson’s Janssen vaccine has now been halted across the US, Europe and South Africa, with health authorities investigating six incidents of clotting in younger women, one of them fatal. The US-developed vaccine uses an adenovirus to trigger immunity – the same mechanism as the UK’s AstraZeneca vaccine. It accounts for roughly 5 percent of vaccines delivered so far in the US. This is a setback to Europe, too. Johnson and Johnson announced it will delay it’s rollout on the continent. The company had already started processing an order from the EU of 200 million doses. The Janssen jab has been partially rolled out in Africa, where a majority of countries don’t have enough vaccines even for their healthcare workers. The African Union signed a deal for 220 million doses this year. But US authorities remain hopeful. They’re saying it could only be a matter of days before the rollout resumes.